There is currently no nationally agreed, evidence-based risk stratification model for glaucoma care. We are funding an innovation grant which will evaluate a risk stratification tool to identify patients with glaucoma at higher risk of vision loss.

The challenge

Glaucoma is the leading cause of preventable sight loss in the United Kingdom and is responsible for almost a third of new vision impairment certifications. The Covid-19 pandemic has re-emphasised the need for a safe and practical risk algorithm to help ensure timely monitoring of glaucoma care during both normal and extraordinary times. 

Over 1 million

glaucoma related visits occur yearly in the NHS

Learn more about glaucoma

Learn more

Glaucoma is when damage to the optic nerve causes sight loss. This is usually due to pressure in your eye rising too high which can develop gradually over the years.

The fluid inside our eyes helps it to keep its shape and function properly. If too much fluid builds up inside the eye, the pressure squeezes the optic nerve at the back of the eye. This can damage the optic nerve made up of million fibres which send signals from the eye to the brain, helping us to see.

Pressure can build in the eye when:

  • fluid is no longer able to drain
  • extra fluid is produced due to an eye injury or infection – this is referred as secondary glaucoma’
  • an abnormality in the shape of the eye in children – this is referred as congenital glaucoma’

It is currently not possible to repair the damage to the optic nerve, therefore any vision lost to glaucoma cannot be recovered. If left untreated, glaucoma can progress to further sight loss.

As there is no cure for glaucoma, current approaches rely on careful monitoring and regular treatment to retain useful sight. There are usually no symptoms of rising pressure in the eye until some vision loss occurs, therefore frequent eye tests are imperative to early onset of glaucoma.

Finding a solution

Along with colleagues, Moorfields consultant Dr Hari Jayaram aims to validate the Glauc-Strat 4” glaucoma risk stratification tool. This system was developed by UK and international specialists but has yet to be validated. This project will take advantage of available data from the Laser in Glaucoma and Ocular Hypertension (LiGHT) trial by using six years of comprehensive clinical follow up-data from 700 patients with glaucoma.

Specifically, the project aims to:

  • compare Glauc-Strat 4” stratification using baseline data to actual clinical outcomes after six years of follow-up
  • evaluate whether mobility of individual patient’s stratified risk correlates with other objective measures of clinical deterioration
  • refine and re-validate the stratification tool in order to optimise its correlation with long-term outcomes

The potential

Assessing the performance of Glauc-Strat 4” to stratify patients could help support the delivery of safe and timely glaucoma care. As a result, this system has the potential to shape the future delivery of glaucoma care at a national level. 

Project Details

Funding scheme

Innovation grant

Grant holder

Dr Hari Jayaram

Area(s) of work

Glaucoma, Service improvement, Patient experience

Start date

June 2020

Grant reference

GR001214